Description
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by guests Erik Andrews, MD, MPH, and Christian Thomas Ruff, MD, MPH, of Brigham and Women's Hospital to discuss Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. In the FRAIL-AF clinical trial, there were more bleeding events when elderly patients were switched from warfarin to rivaroxaban, apixaban, edoxaban, or dabigatran.
Learning Objectives
- To discuss the outcomes of the research paper, "Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial."
Article Authors and Podcast Contributors
Article Authors
Linda P.T. Joosten, MD, Sander van Doorn, MD, PhD, Peter M. van de Ven, PhD, Bart T.G. Köhlen, Melchior C. Nierman, MD, PhD, Huiberdina L. Koek, MD, PhD, Martin E.W. Hemels, MD, PhD, Menno V. Huisman, MD, PhD, Marieke Kruip, MD,PhD, Laura M. Faber, MD, PhD, Nynke M. Wiersma, MD, Wim F., Rob Fijnheer, MD, PhD, Henk J. Adriaansen, MD, PhD, Kit C. Roes, PhD, Arno W. Hoes, MD, PhD, Frans H. Rutten MD, PhD, Geert-Jan Geersing MD, PhD
Podcast Contributors
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital
Erik Andrews, MD, MPH, of Brigham and Women’s Hospital
Christian Thomas Ruff, MD, MPH, of Brigham and Women's Hospital
Disclosures
All relevant financial relationships have been mitigated.Host Disclosure(s):
W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic
Contributor Disclosure(s):
E. Andrews: No relevant financial relationships with ineligible companies to disclose.
C. Ruff: Honoraria/Speaking/Consulting Fee: Bayer Healthcare Pharmaceuticals, Janssen Pharmaceuticals, Daiichi, Boehringer Ingelheim, Bristol-Myers Squibb, Portola Pharmaceuticals; Research (Contracted Grants for PIs Named Investigators Only): Daiichi, MedImmune
Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
S. Sailor: No relevant financial relationships with ineligible companies to disclose.